middle.news
NeuroScientific Advances StemSmart with $4.69M Loss in FY2026
5:52pm on Tuesday 25th of August, 2026 AEST
•
Healthcare
Read Story
NeuroScientific Advances StemSmart with $4.69M Loss in FY2026
5:52pm on Tuesday 25th of August, 2026 AEST
Key Points
Net loss widens to $4.69 million on increased R&D spending
StemSmart™ technology advances with positive clinical outcomes and manufacturing transfer
Phase 2 trials for treatment-resistant Crohn’s disease planned
EmtinB glaucoma asset fully impaired; out-licensing pursued
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE